Voyageur Pharmaceuticals Ltd (VM) - Net Assets
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) has net assets worth CA$1.25 Million CAD (≈ $906.00K USD) as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$3.11 Million ≈ $2.25 Million USD) and total liabilities (CA$1.85 Million ≈ $1.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Voyageur Pharmaceuticals Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$1.25 Million |
| % of Total Assets | 40.33% |
| Annual Growth Rate | 14.64% |
| 5-Year Change | -34.3% |
| 10-Year Change | 86.8% |
| Growth Volatility | 243.67 |
Voyageur Pharmaceuticals Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Voyageur Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Voyageur Pharmaceuticals Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Voyageur Pharmaceuticals Ltd (2011–2025)
The table below shows the annual net assets of Voyageur Pharmaceuticals Ltd from 2011 to 2025. For live valuation and market cap data, see Voyageur Pharmaceuticals Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-11-30 | CA$1.25 Million ≈ $906.00K |
+178.35% |
| 2024-11-30 | CA$449.96K ≈ $325.49K |
-68.66% |
| 2023-11-30 | CA$1.44 Million ≈ $1.04 Million |
-1.97% |
| 2022-11-30 | CA$1.46 Million ≈ $1.06 Million |
-23.17% |
| 2021-11-30 | CA$1.91 Million ≈ $1.38 Million |
+522.25% |
| 2020-11-30 | CA$306.33K ≈ $221.60K |
-59.38% |
| 2019-11-30 | CA$754.09K ≈ $545.50K |
+46.23% |
| 2018-11-30 | CA$515.68K ≈ $373.04K |
+677.88% |
| 2017-11-30 | CA$-89.24K ≈ $-64.55K |
-113.31% |
| 2016-11-30 | CA$670.46K ≈ $485.00K |
+737.30% |
| 2015-11-30 | CA$80.07K ≈ $57.92K |
-1.82% |
| 2014-11-30 | CA$81.56K ≈ $59.00K |
-53.67% |
| 2013-11-30 | CA$176.02K ≈ $127.33K |
-20.48% |
| 2012-11-30 | CA$221.34K ≈ $160.12K |
+19.64% |
| 2011-11-30 | CA$185.00K ≈ $133.83K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Voyageur Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1436759300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$15.62 Million | 1247.17% |
| Total Equity | CA$1.25 Million | 100.00% |
Voyageur Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CAM Resources Bhd
KLSE:7128
|
$14.21 Million |
|
Omineca Mining and Metals Ltd
V:OMM
|
$14.22 Million |
|
Hampton Financial Corp
V:HFC
|
$14.22 Million |
|
JOY SPREADER GROUP INC.
F:5YN
|
$14.23 Million |
|
Polyrizon Ltd. Ordinary Shares
NASDAQ:PLRZ
|
$14.20 Million |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
$14.19 Million |
|
Grand Baoxin Auto Group Limited
F:6BA
|
$14.19 Million |
|
Vo2 Cap Holding AB
ST:VO2
|
$14.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Voyageur Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 449,958 to 1,252,442, a change of 802,484 (178.3%).
- Net loss of 3,532,558 reduced equity.
- New share issuances of 913,881 increased equity.
- Other factors increased equity by 3,421,161.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-3.53 Million | -282.05% |
| Share Issuances | CA$913.88K | +72.97% |
| Other Changes | CA$3.42 Million | +273.16% |
| Total Change | CA$- | 178.35% |
Book Value vs Market Value Analysis
This analysis compares Voyageur Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.55x to 15.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-11-30 | CA$0.20 | CA$0.11 | x |
| 2012-11-30 | CA$0.35 | CA$0.11 | x |
| 2013-11-30 | CA$0.17 | CA$0.11 | x |
| 2014-11-30 | CA$0.08 | CA$0.11 | x |
| 2015-11-30 | CA$0.08 | CA$0.11 | x |
| 2016-11-30 | CA$0.67 | CA$0.11 | x |
| 2017-11-30 | CA$0.00 | CA$0.11 | x |
| 2018-11-30 | CA$0.01 | CA$0.11 | x |
| 2019-11-30 | CA$0.01 | CA$0.11 | x |
| 2020-11-30 | CA$0.00 | CA$0.11 | x |
| 2021-11-30 | CA$0.02 | CA$0.11 | x |
| 2022-11-30 | CA$0.01 | CA$0.11 | x |
| 2023-11-30 | CA$0.01 | CA$0.11 | x |
| 2024-11-30 | CA$0.00 | CA$0.11 | x |
| 2025-11-30 | CA$0.01 | CA$0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Voyageur Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -282.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30231.56%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.48x
- Recent ROE (-282.05%) is below the historical average (-123.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -38.64% | 0.00% | 0.00x | 1.11x | CA$-107.65K |
| 2013 | -25.75% | 0.00% | 0.00x | 1.05x | CA$-62.93K |
| 2014 | -115.82% | 0.00% | 0.00x | 1.96x | CA$-102.62K |
| 2015 | -1.85% | 0.00% | 0.00x | 1.12x | CA$-9.49K |
| 2016 | -7.80% | 0.00% | 0.00x | 1.06x | CA$-119.37K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-661.83K |
| 2018 | -107.79% | 0.00% | 0.00x | 2.46x | CA$-607.43K |
| 2019 | -73.24% | 0.00% | 0.00x | 2.13x | CA$-627.70K |
| 2020 | -371.95% | 0.00% | 0.00x | 4.16x | CA$-1.17 Million |
| 2021 | -107.62% | 0.00% | 0.00x | 1.35x | CA$-2.24 Million |
| 2022 | -119.75% | 0.00% | 0.00x | 1.43x | CA$-1.90 Million |
| 2023 | -97.47% | 0.00% | 0.00x | 1.51x | CA$-1.54 Million |
| 2024 | -379.42% | 0.00% | 0.00x | 5.77x | CA$-1.75 Million |
| 2025 | -282.05% | -30231.56% | 0.00x | 2.48x | CA$-3.66 Million |
Industry Comparison
This section compares Voyageur Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $739,937,582
- Average return on equity (ROE) among peers: -40.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Voyageur Pharmaceuticals Ltd (VM) | CA$1.25 Million | -38.64% | 1.48x | $14.21 Million |
| Aurora Cannabis Inc (ACB) | $601.87 Million | -11.52% | 0.39x | $193.63 Million |
| Amotiv Limited (AOV) | $915.11 Million | 1.59% | 0.43x | $553.67 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-4.29 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $841.07K | -309.08% | 1.52x | $13.17 Million |
| Avant Brands Inc (AVNT) | $-490.96K | 0.00% | 0.00x | $4.13 Million |
| Bausch Health Companies Inc (BHC) | $5.23 Billion | -16.55% | 4.34x | $2.06 Billion |
| CanadaBis Capital Inc (CANB) | $150.00K | 0.00% | 0.00x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $550.08 Million | -25.79% | 1.50x | $12.59 Million |
| Cipher Pharmaceuticals Inc (CPH) | $80.52 Million | 25.31% | 0.07x | $326.62 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $22.27 Million | -71.36% | 0.11x | $148.65 Million |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more